Open Access Peer-reviewed Review

How antidepressants affect the cerebral ischemic injury and ischemic stroke

Main Article Content

Xiaohui Sun
Tian Wang
Lin Zhou
Yawen Yu
Zhaofeng Liu
Runchen Ma
Fenghua Fu corresponding author


Ischemic stroke is the main cause of long-term disability and death worldwide. Studies have pointed out that antidepressants not only can be used to treat depression, but also promote nerve regeneration, nerve plasticity, and recovery of nerve function after stroke. Some evidences indicated that antidepressants have beneficial effects on ischemic stroke. At the same time, there are also risks in treatment process. The mechanisms of the effects of antidepressants on ischemic stroke are complicated and rarely reported. This review summarizes the roles of antidepressants in patients and animal models of stroke, the possible mechanisms of antidepressants against brain injury induced by stroke, and the risks and challenges of antidepressants treatment in patients with ischemia.

ischemic stroke, antidepressants, brain protection

Article Details

Supporting Agencies
This study was supported by grants from the Taishan Scholar Project of Shandong Province.
How to Cite
Sun, X., Wang, T., Zhou, L., Yu, Y., Liu, Z., Ma, R., & Fu, F. (2023). How antidepressants affect the cerebral ischemic injury and ischemic stroke. Journal of Pharmaceutical and Biopharmaceutical Research, 4(2), 318-325.


  1. Randolph SA. Ischemic Stroke. Workplace health & safety, 2016, 64(9): 444.
  2. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke, 2009, 40(3): 111-114.
  3. Jin Y, Lim CM, Kim SW, et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain research, 2009, 1281: 108-116.
  4. Ön BI, Vidal X, Berger U, et al. Antidepressant use and stroke or mortality risk in the elderly. European journal of neurology, 2022, 29(2): 469-477.
  5. Mortensen JK and Andersen G. Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance. Expert opinion on pharmacotherapy, 2021, 22(9): 1157-1166.
  6. Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabilitation and Neural Repair, 2017, 31(7): 638-647.
  7. Chollet F, Acket B, Raposo N, et al. Use of antidepressant medications to improve outcomes after stroke. Current Neurology and Neuroscience Reports, 2013, 13(1): 318.
  8. Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgraduate Medicine, 2017, 129(1): 140-148.
  9. Cao JX, Liu L, Sun YT, et al. Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Brazilian Journal of Medical and Biological Research, 2020, 53(11): 8930.
  10. Lee JY, Lee HE, Kang SR, et al. Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood-brain barrier disruption. Neuropharmacology, 2014, 79: 161-171.
  11. Hua Y, Li C, Hu J, et al. Fluoxetine adjunct to therapeutic exercise promotes motor recovery in rats with cerebral ischemia: Roles of nucleus accumbens. Brain Research Bulletin, 2019, 153: 1-7.
  12. Sheikholeslami MA, Ghafghazi S, Pouriran R, et al. Attenuating effect of paroxetine on memory impairment following cerebral ischemia-reperfusion injury in rat: The involvement of BDNF and antioxidant capacity. European Journal of Pharmacology, 2021, 893: 173821.
  13. Khawam EA, Laurencic G, Malone DA, et al. Side effects of antidepressants: an overview. Cleveland Clinic Journal of Medicine, 2006, 73(4): 351-356.
  14. Kumar A, Garg R, Gaur V, et al. Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain Research, 2010, 1311: 73-80.
  15. Toda T, Yamamoto S, Umehara N, et al. Protective Effects of Duloxetine against Cerebral Ischemia-Reperfusion Injury via Transient Receptor Potential Melastatin 2 Inhibition. The Journal of Pharmacology and Experimental Therapeutics, 2019, 368(2): 246-254.
  16. Liu Y, Feng S, Subedi K, et al. Attenuation of Ischemic Stroke-Caused Brain Injury by a Monoamine Oxidase Inhibitor Involves Improved Proteostasis and Reduced Neuroinflammation. Molecular Neurobiology, 2020, 57(2): 937-948.
  17. Naoi M, Riederer P and Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. Journal of Neural Transmission, 2016, 123(2): 91-106.
  18. Burns MM and Greenberg DA. Antidepressants in the treatment of stroke. Expert review of neurotherapeutics, 2010, 10(8): 1237-1241.
  19. Reeta K, Prabhakar P and Gupta YK. Anticonvulsant activity of the antidepressant drug, tianeptine, against pentylenetetrazole-induced seizures mitigates cognitive impairment in rats. Behavioural Pharmacology, 2016, 27(7): 623-632.
  20. Marinescu IP, Predescu A, Udriştoiu T, et al. Comparative study of neuroprotective effect of tricyclics vs. trazodone on animal model of depressive disorder. Romanian Journal of Morphology and Embryology, 2012, 53(2): 397-400.
  21. Settimo L and Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. Journal of Psychopharmacology, 2018, 32(1): 96-104.
  22. Alkan T, Kahveci N, Buyukuysal L, et al. Neuroprotective effects of MK 801 and hypothermia used alone and in combination in hypoxic-ischemic brain injury in neonatal rats. Archives of Physiology and Biochemistry, 2001, 109(2): 135-144.
  23. Siepmann T, Penzlin AI, Kepplinger J, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain and Behavior, 2015, 5(10): 00373.
  24. Chung YC, Kim SR, Park JY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology, 2011, 60(6): 963-974.
  25. Chen SD, Yang DI, Lin TK, et al. Roles of oxidative stress, apoptosis, PGC-1$alpha$ and mitochondrial biogenesis in cerebral ischemia. International Journal of Molecular Sciences, 2011, 12(10): 7199-7215.
  26. Lim CM, Kim SW, Park JY, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research, 2009, 87(4): 1037-1045.
  27. Shariq AS, Brietzke E, Rosenblat JD, et al. Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Reviews in the Neurosciences, 2018, 30(1): 1-7.
  28. Sacre S, Jaxa-Chamiec A, Low CMR, et al. Structural Modification of the Antidepressant Mianserin Suggests That Its Anti-inflammatory Activity May Be Independent of 5-Hydroxytryptamine Receptors. Frontiers in Immunology, 2019, 10: 1167.
  29. Li M, Liu J, Bi Y, et al. Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia. Current Neuropharmacology, 2018, 16(2): 160-175.
  30. Martín-Hernández D, Bris ÁG, MacDowell KS, et al. Modulation of the antioxidant nuclear factor (erythroid 2-derived)-like 2 pathway by antidepressants in rats. Neuropharmacology, 2016, 103: 79-91.
  31. Dhami KS, Churchward MA, Baker GB, et al. Fluoxetine and its metabolite norfluoxetine induce microglial apoptosis. Journal of Neurochemistry, 2019, 148(6): 761-778.
  32. Elmorsy E, Al-Ghafari A, Almutairi FM, et al. Antidepressants are cytotoxic to rat primary blood brain barrier endothelial cells at high therapeutic concentrations. Toxicology in Vitro, 2017, 44: 154-163.
  33. Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opinion on Pharmacotherapy, 2017, 18(10): 1011-1017.
  34. Jun-O'Connell AH, Jayaraman DK, Henninger N, et al. Effects of Preexisting Psychotropic Medication Use on a Cohort of Patients with Ischemic Stroke Outcome. Stroke Research and Treatment, 2020, 2020: 9070486.
  35. Gaur V and Kumar A. Protective effect of desipramine, venlafaxine and trazodone against experimental animal model of transient global ischemia: possible involvement of NO-cGMP pathway. Brain Research, 2010, 1353: 204-212.
  36. Fang S, Yan B, Wang D, et al. Chronic effects of venlafaxine on synaptophysin and neuronal cell adhesion molecule in the hippocampus of cerebral ischemic mice. Biochemistry and Cell Biology, 2010, 88(4): 655-663.
  37. Robol E, Fiaschi A and Manganotti P. Effects of citalopram on the excitability of the human motor cortex: a paired magnetic stimulation study. Journal of the Neurological Sciences, 2004, 221(1-2): 41-46.
  38. Li X and Morton SM. Effects of chronic antidepressant use on neurophysiological responses to tDCS post-stroke. Neuroscience Letters, 2020, 717: 134723.
  39. Ilic TV, Korchounov A and Ziemann U. Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline. Neuroscience Letters, 2002, 319(2): 116-120.
  40. Gerdelat-Mas A, Loubinoux I, Tombari D, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. NeuroImage, 2005, 27(2): 314-322.
  41. Shin TK, Kang MS, Lee HY, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. The Korean Journal of Physiology & Pharmacology, 2009, 13(3): 257-263.
  42. Narushima K, Paradiso S, Moser DJ, et al. Effect of antidepressant therapy on executive function after stroke. The British Journal of Psychiatry, 2007, 190(3): 260-265.
  43. Smoller JW. Do antidepressants raise the risk of stroke? The American Journal of Psychiatry, 2011, 168(5): 457-459.
  44. Trifirò G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. Journal of Clinical Psychopharmacology, 2010, 30(3): 252-258.
  45. Hoirisch-Clapauch S and Nardi AE. Antidepressants: bleeding or thrombosis? Thrombosis Research, 2019, 181(1): 23-28.
  46. Pericaud A, Straczek C, Montastruc F, et al. Use of antidepressants in unipolar depression in the elderly. L'Encephale, 2022, 48(4): 445-454.
  47. Glymour MM, Gibbons LE, Gilsanz P, et al. Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding. Annals of Epidemiology, 2019, 35: 42-47.
  48. Tully PJ, Alpérovitch A, Soumaré A, et al. Association Between Cerebral Small Vessel Disease With Antidepressant Use and Depression: 3C Dijon Magnetic Resonance Imaging Study. Stroke, 2020, 51(2): 402-408.
  49. Legg LA, Rudberg AS, Hua X, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. The Cochrane Database of Systematic Reviews, 2021, 11(11): 009286.
  50. Juang HT, Chen PC and Chien KL. Using antidepressants and the risk of stroke recurrence: report from a national representative cohort study. BMC Neurology, 2015, 15: 86.
  51. Avuloglu Yilmaz E, Unal F and Yuzbasioglu D. Evaluation of cytogenetic and DNA damage induced by the antidepressant drug-active ingredients, trazodone and milnacipran, in vitro. Drug and Chemical Toxicology, 2017, 40(1): 57-66.
  52. Braillon A. Antidepressants after stroke and patient centered care: An oxymoron. Research in Social & Administrative Pharmacy, 2019, 15(9): 1187-1188.
  53. Soh Y, Tiemeier H, Kawachi I, et al. Eight-Year Depressive Symptom Trajectories and Incident Stroke: A 10-Year Follow-Up of the HRS (Health and Retirement Study). Stroke, 2022, 53(8): 2569-2576.
  54. Li H, Zheng D, Li Z, et al. Association of Depressive Symptoms With Incident Cardiovascular Diseases in Middle-Aged and Older Chinese Adults. JAMA Network Open, 2019, 2(12): 1916591.
  55. McCann SK, Irvine C, Mead GE, et al. Efficacy of antidepressants in animal models of ischemic stroke: a systematic review and meta-analysis. Stroke, 2014, 45(10): 3055-3063.